Daxor Corporation Announces Partial Exercise of Over-Allotment Option in Secondary Offering
22 Junho 2023 - 5:15PM
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume
measurement technology, today announced that Maxim Group LLC
(“Maxim”), as Representative of several Underwriters of its
previously announced secondary public offering have partially
exercised their option to purchase an additional 54,339 Option
Shares of Daxor’s Class A common stock (the “Over-Allotment
Option”) at a public price of $9.75 per share.
Delivery of the Option Shares and payment
thereof shall be made on the Closing Date, designated as June 22,
2023, and in accordance with the terms of the Underwriting
Agreement. The manner of closing, including the names, delivery
mechanics and denominations for any certificates evidencing the
Option Shares, shall be as designated in a separate communication
by or on behalf of the Underwriter to the Company.
A registration statement relating to these
securities has been filed with the Securities & Exchange
Commission (the “SEC”) on Form N-2 (File Nos. 333-255212 and
811-22684) on April 13, 2021 that was declared effective by the SEC
on July 16, 2021. A preliminary prospectus supplement and
accompanying prospectus relating to and describing the terms of the
offering is available on the SEC's website located
at www.sec.gov. A copy of the preliminary prospectus
supplement and accompanying prospectus relating to the offering may
be obtained for free by visiting EDGAR on the SEC website
at www.sec.gov.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Daxor
Corporation
Daxor Corporation (Nasdaq: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the first diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 65,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing multicenter trials in
the areas of COVID-19 and heart failure treatment with support from
the NIH and is under contract developing analyzers to improve
combat casualty care with the U.S. Department of Defense. Daxor's
mission is to advance healthcare by enabling optimal fluid
management with blood volume analysis. Daxor’s vision is optimal
blood volume for all. For more information, please visit our
website at Daxor.com. Sign up to receive news on Daxor’s innovative
technology HERE.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations
Contact:Bret ShapiroSr. Managing Partner, CORE
IR1-516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Daxor (NASDAQ:DXR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024